
REMARKS

This paper is responsive to an Office Action dated May 25, 2005. Prior to this response claims 1-38 were pending. After amending claims 1, 6, 20, 30-31, 33, and 37, and canceling claims 3-5, 19, and 22-29, claims 1-2, 6-18, 20-21, and 30-38 remain pending.

In Section 2 of the Office Action, claims 1-18, 20-28, and 31-38 have been rejected as anticipated under 35 U.S.C. 102(b) with respect to Balakrishnan (US 5,566,208).


Section 3 of the Office Action states that claims 19 and 29-30 would be found allowable if rewritten in independent form, including all the subject matter of the base and intervening claims. In response, claim 1 has been amended to include the subject matter of claims 3-5 and 19 (now canceled). All claims dependent from claim 1 should be found allowable. Likewise, claim 20 has been amended to include the subject matter of claims 22-29 (now canceled). All claims dependent from claim 20 should be allowable.

BEST AVAILABLE COPY

It is believed that the application is in condition for
allowance and reconsideration is earnestly solicited.

Date: 6/17/05

Respectfully submitted,


David Ripma

Registration No. 27,672

Customer Number 27518
David Ripma, Patent Counsel
Sharp Laboratories of America, Inc.
5750 NW Pacific Rim Blvd.
Camas, WA 98607
Telephone: (360) 834-8754
Facsimile: (360) 817-8505

BEST AVAILABLE COPY